FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074339905> ?p ?o ?g. }

• W2074339905 endingPage "1519" @default.
• W2074339905 startingPage "1511" @default.
• W2074339905 abstract "Carcinoid syndrome (CS) is associated with elevated serotonin, diarrhea, flushing, and increased risk of valvular heart disease. Many patients respond to somatostatin analogs initially, but response diminishes in most patients. Additional options are needed. To assess whether telotristat etiprate (TE) can reduce gastrointestinal symptoms in CS and reduce urinary 5-hydroxyindoleacetic acid (u5-HIAA; a biomarker of serotonin). A prospective, exploratory, dose-escalating 12-week, open-label, multicenter study of TE with efficacy and safety analyses. A multicenter study. Eligible patients had metastatic, well-differentiated, neuroendocrine tumors and CS with ≥ four bowel movements (BMs) per day. Somatostatin analog use was allowed. TE, a novel oral inhibitor of peripheral serotonin synthesis. Primary: safety. Secondary: daily BMs, stool form, and u5-HIAA. Fifteen patients were enrolled, and 14 completed the treatment period. All patients experienced reductions in BMs per day (mean decrease, 43.5%). A 74.2% mean reduction in u5-HIAA, the main metabolite of serotonin, was observed, with generally greater reductions in patients with greater reductions in BMs per day. Nine patients (75%) reported “adequate relief” of gastrointestinal symptoms at 12 weeks, compared with two (17%) at baseline. Stool form and flushing also improved. Adverse events were mostly gastrointestinal (n = 10; 67%), consistent with underlying illness; three adverse events were serious (abdominal pain, diarrhea, and gastroenteritis) but were judged unrelated. TE was generally safe and well tolerated. Patients experienced substantial improvement in CS and reductions in u5-HIAA, consistent with the mechanism of action of TE. These results support further evaluation in phase 3 studies." @default.
• W2074339905 created "2016-06-24" @default.
• W2074339905 creator A5003454059 @default.
• W2074339905 creator A5007891817 @default.
• W2074339905 creator A5009110738 @default.
• W2074339905 creator A5011951334 @default.
• W2074339905 creator A5021152840 @default.
• W2074339905 creator A5026573275 @default.
• W2074339905 creator A5040261977 @default.
• W2074339905 creator A5041036914 @default.
• W2074339905 creator A5050005771 @default.
• W2074339905 creator A5055143638 @default.
• W2074339905 creator A5075068326 @default.
• W2074339905 creator A5083493576 @default.
• W2074339905 date "2015-04-01" @default.
• W2074339905 modified "2023-09-30" @default.
• W2074339905 title "Telotristat Etiprate for Carcinoid Syndrome: A Single-Arm, Multicenter Trial" @default.
• W2074339905 cites W1968424817 @default.
• W2074339905 cites W1999440266 @default.
• W2074339905 cites W2017099595 @default.
• W2074339905 cites W2028714832 @default.
• W2074339905 cites W2066173933 @default.
• W2074339905 cites W2075083707 @default.
• W2074339905 cites W2080448046 @default.
• W2074339905 cites W2082472122 @default.
• W2074339905 cites W2089429746 @default.
• W2074339905 cites W2125332438 @default.
• W2074339905 cites W2278220001 @default.
• W2074339905 cites W2339078872 @default.
• W2074339905 cites W2408565076 @default.
• W2074339905 doi "https://doi.org/10.1210/jc.2014-2247" @default.
• W2074339905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25636046" @default.
• W2074339905 hasPublicationYear "2015" @default.
• W2074339905 type Work @default.
• W2074339905 sameAs 2074339905 @default.
• W2074339905 citedByCount "92" @default.
• W2074339905 countsByYear W20743399052015 @default.
• W2074339905 countsByYear W20743399052016 @default.
• W2074339905 countsByYear W20743399052017 @default.
• W2074339905 countsByYear W20743399052018 @default.
• W2074339905 countsByYear W20743399052019 @default.
• W2074339905 countsByYear W20743399052020 @default.
• W2074339905 countsByYear W20743399052021 @default.
• W2074339905 countsByYear W20743399052022 @default.
• W2074339905 countsByYear W20743399052023 @default.
• W2074339905 crossrefType "journal-article" @default.
• W2074339905 hasAuthorship W2074339905A5003454059 @default.
• W2074339905 hasAuthorship W2074339905A5007891817 @default.
• W2074339905 hasAuthorship W2074339905A5009110738 @default.
• W2074339905 hasAuthorship W2074339905A5011951334 @default.
• W2074339905 hasAuthorship W2074339905A5021152840 @default.
• W2074339905 hasAuthorship W2074339905A5026573275 @default.
• W2074339905 hasAuthorship W2074339905A5040261977 @default.
• W2074339905 hasAuthorship W2074339905A5041036914 @default.
• W2074339905 hasAuthorship W2074339905A5050005771 @default.
• W2074339905 hasAuthorship W2074339905A5055143638 @default.
• W2074339905 hasAuthorship W2074339905A5075068326 @default.
• W2074339905 hasAuthorship W2074339905A5083493576 @default.
• W2074339905 hasBestOaLocation W20743399051 @default.
• W2074339905 hasConcept C126322002 @default.
• W2074339905 hasConcept C168563851 @default.
• W2074339905 hasConcept C170493617 @default.
• W2074339905 hasConcept C197934379 @default.
• W2074339905 hasConcept C2775864247 @default.
• W2074339905 hasConcept C2775965419 @default.
• W2074339905 hasConcept C2776297358 @default.
• W2074339905 hasConcept C2777573665 @default.
• W2074339905 hasConcept C2778271842 @default.
• W2074339905 hasConcept C2778375690 @default.
• W2074339905 hasConcept C2779802037 @default.
• W2074339905 hasConcept C2780955771 @default.
• W2074339905 hasConcept C2781151469 @default.
• W2074339905 hasConcept C2992435398 @default.
• W2074339905 hasConcept C71924100 @default.
• W2074339905 hasConcept C90924648 @default.
• W2074339905 hasConceptScore W2074339905C126322002 @default.
• W2074339905 hasConceptScore W2074339905C168563851 @default.
• W2074339905 hasConceptScore W2074339905C170493617 @default.
• W2074339905 hasConceptScore W2074339905C197934379 @default.
• W2074339905 hasConceptScore W2074339905C2775864247 @default.
• W2074339905 hasConceptScore W2074339905C2775965419 @default.
• W2074339905 hasConceptScore W2074339905C2776297358 @default.
• W2074339905 hasConceptScore W2074339905C2777573665 @default.
• W2074339905 hasConceptScore W2074339905C2778271842 @default.
• W2074339905 hasConceptScore W2074339905C2778375690 @default.
• W2074339905 hasConceptScore W2074339905C2779802037 @default.
• W2074339905 hasConceptScore W2074339905C2780955771 @default.
• W2074339905 hasConceptScore W2074339905C2781151469 @default.
• W2074339905 hasConceptScore W2074339905C2992435398 @default.
• W2074339905 hasConceptScore W2074339905C71924100 @default.
• W2074339905 hasConceptScore W2074339905C90924648 @default.
• W2074339905 hasIssue "4" @default.
• W2074339905 hasLocation W20743399051 @default.
• W2074339905 hasLocation W20743399052 @default.
• W2074339905 hasOpenAccess W2074339905 @default.
• W2074339905 hasPrimaryLocation W20743399051 @default.
• W2074339905 hasRelatedWork W122747164 @default.
• W2074339905 hasRelatedWork W2357684900 @default.

• next